Project

MERLIN

Exploring BMI1’s Role in Osimertinib Resistance and EGFR Mutation-Specific Metabolic Reprogramming in NSCLC
Application Areas
Research Areas
Research Lines
Staff
WEBSITE

ITB Principal Investigator

Name

Exploring BMI1’s Role in Osimertinib Resistance and EGFR Mutation-Specific Metabolic Reprogramming in NSCLC

Acronym

MERLIN

Location

Pisa

Start Date

2025

End Date

2027

Funder

FPS Foundation for Pisan Science ONLUS

Partners

CNR ICCOM Pisa Dr.ssa Emilia Bramanti

The main goal of this project is to investigate osimertinib resistance in EGFR-mutant tumors and assess the therapeutic potential of BMI1 inhibition. The study combines single-cell RNA sequencing and metabolomics to understand the metabolic alterations driving resistance, with advanced microscopy to closely examine intracellular organelles, such as mitochondria, and extracellular structures, including vesicles and nuclei, linking molecular mechanisms to cellular and functional characteristics.